Youssef A Elnabawi1, Michael S Garshick2, Michael Tawil3, Tessa J Barrett3, Edward A Fisher4, Kristen Lo Sicco5, Andrea L Neimann5, Jose U Scher6, James Krueger7, Jeffrey S Berger8. 1. Department of Internal Medicine, New York University School of Medicine, New York, New York. 2. Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, New York; Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, New York. Electronic address: michael.garshick@nyulangone.org. 3. Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, New York. 4. Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, New York; Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, New York. 5. Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York. 6. Psoriatic Arthritis Center, Division of Rheumatology, New York University School of Medicine, New York, New York. 7. Laboratory for Investigative Dermatology, Rockefeller University, New York, New York. 8. Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, New York; Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, New York; Division of Hematology, New York University School of Medicine, New York, New York; Division of Vascular Surgery, Department of Surgery, New York University School of Medicine, New York, New York.
Abstract
BACKGROUND: Psoriasis is associated with increased cardiovascular risk that is not captured by traditional proinflammatory biomarkers. OBJECTIVE: To investigate the relationship between Psoriasis Area and Severity Index, circulating proinflammatory biomarkers, and vascular health in psoriasis. METHODS: In patients with psoriasis and in age and sex-matched controls, 273 proteins were analyzed with the Proseek Multiplex Cardiovascular disease reagents kit and Inflammatory reagents kit (Olink Bioscience), whereas vascular endothelial inflammation and health were measured via direct transcriptomic analysis of brachial vein endothelial cells. RESULTS: In psoriasis, chemokine ligand 20 (CCL20), interleukin (IL) 6, and IL-17A were the top 3 circulating proinflammatory cytokines. Vascular endothelial inflammation correlated with CCL20 (r = 0.55; P < .001) and less so with IL-6 (r = 0.36; P = .04) and IL-17A (r = 0.29; P = .12). After adjustment for potential confounders, the association between CCL20 and vascular endothelial inflammation remained significant (β = 1.71; P = .02). In nested models, CCL20 added value (χ2 = 79.22; P < .001) to a model already incorporating the Psoriasis Area and Severity Index, Framingham risk, high-sensitivity C-reactive protein, Il-17A, and IL-6 (χ2 = 48.18; P < .001) in predicting vascular endothelial inflammation. LIMITATIONS: Our study was observational and did not allow for causal inference in the relationship between CCL20 and cardiovascular risk. CONCLUSION: We demonstrate that CCL20 expression has a strong association with vascular endothelial inflammation, reflects systemic inflammation, and may serve as a potential biomarker of impaired vascular health in psoriasis.
BACKGROUND: Psoriasis is associated with increased cardiovascular risk that is not captured by traditional proinflammatory biomarkers. OBJECTIVE: To investigate the relationship between Psoriasis Area and Severity Index, circulating proinflammatory biomarkers, and vascular health in psoriasis. METHODS: In patients with psoriasis and in age and sex-matched controls, 273 proteins were analyzed with the Proseek Multiplex Cardiovascular disease reagents kit and Inflammatory reagents kit (Olink Bioscience), whereas vascular endothelial inflammation and health were measured via direct transcriptomic analysis of brachial vein endothelial cells. RESULTS: In psoriasis, chemokine ligand 20 (CCL20), interleukin (IL) 6, and IL-17A were the top 3 circulating proinflammatory cytokines. Vascular endothelial inflammation correlated with CCL20 (r = 0.55; P < .001) and less so with IL-6 (r = 0.36; P = .04) and IL-17A (r = 0.29; P = .12). After adjustment for potential confounders, the association between CCL20 and vascular endothelial inflammation remained significant (β = 1.71; P = .02). In nested models, CCL20 added value (χ2 = 79.22; P < .001) to a model already incorporating the Psoriasis Area and Severity Index, Framingham risk, high-sensitivity C-reactive protein, Il-17A, and IL-6 (χ2 = 48.18; P < .001) in predicting vascular endothelial inflammation. LIMITATIONS: Our study was observational and did not allow for causal inference in the relationship between CCL20 and cardiovascular risk. CONCLUSION: We demonstrate that CCL20 expression has a strong association with vascular endothelial inflammation, reflects systemic inflammation, and may serve as a potential biomarker of impaired vascular health in psoriasis.
Authors: Joel M Gelfand; Andrea L Neimann; Daniel B Shin; Xingmei Wang; David J Margolis; Andrea B Troxel Journal: JAMA Date: 2006-10-11 Impact factor: 56.272
Authors: Nehal N Mehta; YiDing Yu; Rebecca Pinnelas; Parasuram Krishnamoorthy; Daniel B Shin; Andrea B Troxel; Joel M Gelfand Journal: Am J Med Date: 2011-08 Impact factor: 4.965
Authors: Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian Journal: Circulation Date: 2019-03-17 Impact factor: 29.690
Authors: Junko Takeshita; Sungat Grewal; Sinéad M Langan; Nehal N Mehta; Alexis Ogdie; Abby S Van Voorhees; Joel M Gelfand Journal: J Am Acad Dermatol Date: 2017-03 Impact factor: 11.527
Authors: Ping-Hsun Wu; Rie Io Glerup; My Hanna Sofia Svensson; Niclas Eriksson; Jeppe Hagstrup Christensen; Philip de Laval; Inga Soveri; Magnus Westerlund; Torbjörn Linde; Östen Ljunggren; Bengt Fellström Journal: Biomedicines Date: 2022-03-22
Authors: Wenjing Li; Kehan Jin; Jichang Luo; Wenlong Xu; Yujie Wu; Jia Zhou; Yilin Wang; Ran Xu; Liqun Jiao; Tao Wang; Ge Yang Journal: Front Cardiovasc Med Date: 2022-09-20
Authors: Hannah Kaiser; Xing Wang; Amanda Kvist-Hansen; Martin Krakauer; Peter Michael Gørtz; Benjamin D McCauley; Lone Skov; Christine Becker; Peter Riis Hansen Journal: Sci Rep Date: 2021-11-02 Impact factor: 4.379
Authors: Vladimir V Sobolev; Anna G Soboleva; Elena V Denisova; Eva A Pechatnikova; Eugenia Dvoryankova; Irina M Korsunskaya; Alexandre Mezentsev Journal: Biomedicines Date: 2022-03-07